Business Wire

Nanoco to Present at Upcoming Industry Conferences

18.2.2025 12:00:00 CET | Business Wire | Press release

Share

Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, is ramping up its commercial engagement as it transitions to scaled production. Over the coming months the company will be attending several key industry events to showcase its technology, connect with its customers and development partners, and to accelerate adoption of its solutions.

In March, Nanoco Founder and CTO Dr. Nigel Pickett will speak at the Society for Information Display (SID) UK Chapter meeting in London. His presentation, “Molecular Seeding Technology for Display Applications and Beyond,” will explain how Nanoco’s technology can enhance micro-LED and other displays, making them more efficient and cost-effective for mass production. As the industry moves toward brighter, more energy-efficient screens, Nanoco is working with partners to bring its technology into commercial products.

Later that month Nanoco will attend and sponsor Image Sensors Europe, a major industry gathering of over 250 vision technology professionals. The team will engage with potential customers and partners, highlighting how Nanoco’s quantum dot-based imaging solutions are unlocking new possibilities across several industries.

In April, Nanoco will be presenting its latest results on Image Sensors at SPIE Defense + Commercial Sensing conference in Orlando, Florida. The presentation, “Molecular Seeding Technology: Enabling Sensing Applications of the Future,” will highlight how Nanoco’s technology enables the production of Quantum Dots at scale making high-performance infrared image sensors more affordable and available. These sensors are in growing demand and Nanoco is positioning itself as a key player in that industry.

Nigel Pickett, Ph.D., the founder and CTO of Nanoco, said:

"Molecular seeding technology is our foundational IP for high volume quantum dot production. It allows us to manufacture high-quality materials efficiently, meeting the strict demands of the electronics industry. We believe it is the only feasible method to manufacture Quantum Dots at scale. This technology has already played a pivotal role in advancing display technologies, and we are now seeing the same potential in quantum dot enabled sensing applications where Nanoco has the largest product portfolio.

Dmitry Shashkov, Ph.D., CEO of Nanoco, said:

"We are excited to present our latest achievements to the industry and take the next steps to align the business with commercial execution. These industry events are not just about presenting technology—they are about building relationships with partners and customers who will be instrumental in bringing QD Image Sensors into mass adoption. We at Nanoco see the next 1-2 years as a major inflection point for the industry, as low-cost, wafer-scale production processes will bring QD Image Sensors to a wide variety of applications, including consumer, automotive, industrial and defense sectors."

About Nanoco Group plc

Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium-free quantum dots (CFQD®) and other nanomaterials for use in the electronics industry. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build a world-class, patent-protected IP portfolio alongside its existing scaled-up production facilities for commercial orders.

For further information, please visit: www.nanocotechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218331567/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release

New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki

Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release

90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release

For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer

tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release

Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye